

Special Issue

Inhibitors in the Treatment of Cancer and Neurodegenerative Disorders

Message from the Guest Editors

Molecular mechanisms that underpin the onset and progression of malignant and neurodegenerative diseases seem to have little in common. Some epidemiological studies add weight to the inverse association between certain types of cancer and neurodegenerative diseases. However, there is no clear consensus on this connotation. Cancer cells escape cell death signals whereas aberrant activation of neuronal cell death is a common hallmark in neurodegenerative diseases. Numerous studies suggest common genetic and epigenetic factors that are implicated in cancer and neurodegeneration. Some of these include p53, ATM gene, Cyclin-dependent kinase 5 (CDK5), glycogen synthase kinase-3 (GSK3), histone deacetylase 2 (HDAC2), Brain-derived Neurotrophic Factor (BDNF), changes in microRNA (miRNA) expression and many more.

To improve our understanding of the crosstalk between cancer and neurodegeneration, this Special Issue aims to discuss the novel therapeutic agents able to target aberrant molecular mechanisms common in cancer and neurodegenerative diseases.

Guest Editors

Prof. Dr. Katarina Nikolic

Prof. Dr. Biljana Bufan

Dr. Dusan Ruzic

Deadline for manuscript submissions

closed (31 January 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/159819

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).